Enlivex Ltd(ENLV) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:31 PM ET (Korea 9/12 08:31)
Full metrics table
| Index | - | P/E | 0 | EPS (ttm) | 382.12 | Insider Own | 89.54% | Shs Outstand | 15.8M | Perf Week | -17.28% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 1.8M | Perf Month | -47.85% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.28 | Inst Own | 1.63% | Short Float | 6.55% | Perf Quarter | -91.1% |
| Income | 1.24B | P/S | - | EPS this Y | - | Inst Trans | 0.63% | Short Ratio | 0.5 | Perf Half Y | -94.02% |
| Sales | 0.00B | P/B | 0.01 | EPS next 5Y | 72.14% | ROA | 104.94% | Short Interest | 0.12M | Perf YTD | -90.9% |
| Book/sh | 122.27 | P/C | 2.86 | EPS past 3/5Y | - | ROE | 126.17% | 52W High | -96.47% ($27.15) | Perf Year | -94.02% |
| Cash/sh | 0.34 | P/FCF | - | Sales past 3/5Y | - | ROIC | 63.84% | 52W Low | -2.07% ($0.98) | Perf 3Y | -96.67% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 3852.04% | Gross Margin | - | Volatility(W/M) | 13.27% 13.04% | Perf 5Y | -99.44% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.23 | Perf 10Y | -99.9% |
| Dividend Ex-Date | - | Quick Ratio | 193.24 | EPS Q/Q | 11884.63% | Profit Margin | - | RSI (14) | 14.64 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 193.24 | Sales Q/Q | - | SMA20 | -28.69% ($1.35) | Beta | 1.37 | Target Price | $80 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/08/24 | SMA50 | -68.57% ($3.05) | Rel Volume | 1.01 | Prev Close | $0.98 |
| Employees | 34 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -91.27% ($11) | Avg Volume(3M) | 0.24M | Price | $0.96 |
| IPO | 2014/7/31 | Option/Short | No/Yes | Trades | 988 | Volume | 240,662 | Change | -2.16% |
Company
ENLV is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Enlivex is a clinical-stage macrophage reprogramming immunotherapy company based in Israel. It is developing cell therapies targeting diseases that require immune modulation, such as osteoarthritis and sepsis, with its lead candidate Allocetra at the forefront. As a development-stage biotech that has not yet generated commercial revenue, its corporate value is shaped by progress in its clinical pipeline and the flow of its funding.
Over the past 1 year, on the lower side
96% below its 1-year high.
ENLV makes money exceptionally well
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +72.1% this year.
Tap to view numbers
The stock looks undervalued
Trading at 0.0 times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -96.7% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 1.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IZRL 0.01%
QQQS 0.00%It ranks #4 in the industry
Based on market cap of $17M.
ENLV $17M PER 0.0
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is ENLV?
ENLV belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ENLV?
The market cap of ENLV is approximately $17M, ranking 5,346 within its sector.
What is the P/E ratio of ENLV?
ENLV has a P/E ratio of approximately 0.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ENLV?
ENLV has recorded a 52-week high of $27.15 and a low of $0.98.
